Why being part of Lunaphore?
Tissue diagnostics is the largest growing segment within the whole IVD (in-vitro diagnostics) market with more than 10% average growth rate during the last 5 years. Between 2011 and 2016, the market, including immunohistochemistry and in-situ hybridization, has doubled to around 2 billion USD. Independent market research reports forecast the same growth rate from now until 2020. Such growth originates from increasing number of not only cancer incidences in the world, but also more and more tests required for each patient.
Laboratory automation has been the key driver of these previously manual technologies. With the automation, test costs are reduced to an applicable level where each patient can profit from such personalized diagnosis. At the same time, reproducibility and reliability of the tests have increased significantly. However, the increasing pressure on even higher number of tests has started to create fundamental bottlenecks in tissue diagnostics labs. Limited investment capabilities of laboratories, limited personnel availability, the need for even higher productivity, and extreme cost-cut pressure can paralyze the laboratories and the health economic system within a few years.
Sooner than later, existing workflow automation systems will be obsolete under the market growth pressure. Lunaphore brings critical innovation in tissue diagnostics based on a breakthrough microfluidic technology: We help labs do more with less.
Are you interested?
We are looking for visionary investors and partners to help us build our solutions and enable our reach to patients.